1 of 1
Story summary
- The Padcev and Keytruda combination reduced the risk of recurrence, progression, or death by 60% in cisplatin-ineligible muscle-invasive bladder cancer.
- Merck & Co., Pfizer Inc., and Astellas Pharma Inc. presented the results at the European Society of Medical Oncology conference in Berlin.
- The combination’s survival remains unmeasured.
- Over 80% survived at least two years on Padcev and Keytruda, compared with 60% for surgery alone.
